Italian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia (MMA) to Phase I/II testing.
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
Italian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia (MMA) to Phase I/II testing.